Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Aug;9(8):2296-2300.
doi: 10.21037/jtd.2017.07.72.

Bioresorbable scaffolds versus metallic stents in routine PCI: the plot thickens

Athanasios Katsikis  1 , Patrick W Serruys  2
Affiliations
Editorial

Bioresorbable scaffolds versus metallic stents in routine PCI: the plot thickens

Athanasios Katsikis et al. J Thorac Dis. 2017 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: PW Serruys is a member of the international advisory board for Abbott. A Katsikis has no conflicts of interest to declare.

Comment in

  • Bioresorbable stents: quo vantis?
    Kounis NG, Koniari I, Davlouros P, Soufras G, Tsigkas G, Hahalis G. Kounis NG, et al. J Thorac Dis. 2017 Nov;9(11):E1032-E1034. doi: 10.21037/jtd.2017.10.62. J Thorac Dis. 2017. PMID: 29268565 Free PMC article. No abstract available.

Comment on

  • Bioresorbable Scaffolds versus Metallic Stents in Routine PCI.
    Wykrzykowska JJ, Kraak RP, Hofma SH, van der Schaaf RJ, Arkenbout EK, IJsselmuiden AJ, Elias J, van Dongen IM, Tijssen RYG, Koch KT, Baan J Jr, Vis MM, de Winter RJ, Piek JJ, Tijssen JGP, Henriques JPS; AIDA Investigators. Wykrzykowska JJ, et al. N Engl J Med. 2017 Jun 15;376(24):2319-2328. doi: 10.1056/NEJMoa1614954. Epub 2017 Mar 29. N Engl J Med. 2017. PMID: 28402237 Clinical Trial.

References

    1. Iqbal J, Onuma Y, Ormiston J, et al. Bioresorbable scaffolds: rationale, current status, challenges, and future. Eur Heart J 2014;35:765-76. 10.1093/eurheartj/eht542 - DOI - PubMed
    1. van der Giessen WJ, Lincoff AM, Schwartz RS, et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996;94:1690-7. 10.1161/01.CIR.94.7.1690 - DOI - PubMed
    1. Serruys PW, Ormiston J, van Geuns RJ, et al. A polylactide bioresorbable scaffold eluting everolimus for treatment of coronary stenosis: 5-year follow-up. J Am Coll Cardiol 2016;67:766-76. 10.1016/j.jacc.2015.11.060 - DOI - PubMed
    1. Ellis SG, Kereiakes DJ, Metzger DC, et al. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med 2015;373:1905-15. 10.1056/NEJMoa1509038 - DOI - PubMed
    1. Chevalier B, Onuma Y, van Boven AJ, et al. Randomised comparison of a bioresorbable everolimus-eluting scaffold with a metallic everolimus-eluting stent for ischaemic heart disease caused by de novo native coronary artery lesions: the 2-year clinical outcomes of the ABSORB II trial. EuroIntervention 2016;12:1102-7. 10.4244/EIJY16M08_01 - DOI - PubMed

LinkOut - more resources